Answers are grounded in this paper and cite their sources.
Trial emulation shows no TSH testing differences between GLP-1 RAs and SGLT-2is in patients on levothyroxine, suggesting missed monitoring opportunities during weight loss.
TSH testing patterns did not differ between GLP-1 RAs and SGLT-2is, despite the greater likelihood of requiring levothyroxine dose adjustment associated with weight loss seen with GLP-1 RAs therapy. Given levothyroxine's widespread use, this gap suggests missed opportunities for timely and weight-responsive thyroid monitoring.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: